$31.3 M

SNBP Mkt cap, 16-Sept-2020
Sun BioPharma Net income (Q2, 2020)-419 K
Sun BioPharma EBIT (Q2, 2020)-1.1 M
Sun BioPharma Cash, 30-Jun-20202.3 M
Sun BioPharma EV29.1 M

Sun BioPharma Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

674.3k299.9k148.6k

Cost of goods sold

381.4k308.0k517.3k

Gross profit

292.8k(8.1k)(368.6k)

Gross profit Margin, %

43%(3%)(248%)

R&D expense

279.8k2.9m2.5m2.6m1.8m2.3m

General and administrative expense

145.2k197.6k664.9k2.6m2.7m3.4m2.1m2.0m

Operating expense total

258.1k609.7k837.2k5.4m5.2m6.0m3.9m4.3m

EBIT

282.8k(194.3k)(75.4k)(5.4m)(5.2m)(6.0m)(3.9m)(4.3m)

EBIT margin, %

42%(65%)(51%)

Interest expense

36.1k239.0k285.0k4.9m2.3m

Interest income

18.4k4.0k

Investment income

8.0k2.0k1.0k

Pre tax profit

(5.7m)(5.5m)(10.9m)(6.2m)(6.6m)

Income tax expense

284.0220.0121.0(756.0k)(341.0k)(536.0k)(254.0k)(415.0k)

Net Income

247.4k(212.0k)(107.0k)(4.9m)(5.1m)(10.4m)(5.9m)(6.2m)

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

63.0k42.5k40.2k36.2k34.8k51.8k36.8k

Cost of goods sold

69.2k72.6k79.8k130.3k124.8k123.2k119.6k

Gross profit

(6.2k)(30.1k)(39.6k)(94.1k)(90.0k)(71.4k)(82.8k)

Gross profit Margin, %

(10%)(71%)(99%)(260%)(259%)(138%)(225%)

R&D expense

341.0k494.0k530.0k636.0k744.0k675.0k530.0k580.0k442.0k450.0k350.0k508.0k720.0k598.0k434.0k

General and administrative expense

21.2k39.2k48.6k163.7k197.8k153.6k189.5k429.0k481.0k419.0k499.0k1.3m487.0k515.0k658.0k654.0k467.0k303.0k580.0k622.0k468.0k670.0k

Operating expense total

40.0k70.1k105.0k205.2k237.2k219.2k230.7k770.0k975.0k949.0k1.1m2.0m1.2m1.0m1.2m1.1m917.0k653.0k1.1m1.3m1.1m1.1m

EBIT

(43.5k)(54.3k)(103.5k)(49.9k)(87.4k)(77.8k)(81.6k)(770.0k)(975.0k)(949.0k)(1.1m)(2.0m)(1.2m)(1.0m)(1.2m)(1.1m)(917.0k)(653.0k)(1.1m)(1.3m)(1.1m)(1.1m)

EBIT margin, %

(69%)(128%)(257%)(138%)(251%)(150%)(222%)

Interest expense

9.0k46.0k36.0k119.0k45.0k3.7m364.0k371.0k543.0k1.5m64.0k999.0k1.3m222.0k

Interest income

3.8k5.2k1.8k1.6k567.0

Investment income

1.0k1.0k1.0k

Pre tax profit

(816.0k)(939.0k)(1.1m)(1.1m)(5.7m)(1.5m)(1.4m)(1.8m)(2.6m)(981.0k)(1.7m)(2.3m)(1.6m)(1.9m)(459.0k)

Income tax expense

200.0220.0121.0198.0(23.0k)(115.0k)(90.0k)(45.0k)(152.0k)(112.0k)(197.0k)(28.0k)(79.0k)(54.0k)(71.0k)(70.0k)(190.0k)(92.0k)(40.0k)

Net Income

(48.8k)(58.2k)(110.6k)(57.3k)(95.7k)(87.8k)(90.1k)(793.0k)(824.0k)(978.0k)(1.1m)(5.6m)(1.4m)(1.2m)(1.8m)(2.5m)(927.0k)(1.6m)(2.3m)(1.4m)(1.8m)(419.0k)

Sun BioPharma Balance Sheet

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

48.6k103.8k71.1k122.9k131.6k238.2k64.8k1.8m383.0k1.9m1.2m2.4m1.2m943.0k1.2m905.0k239.0k1.4m721.0k3.4m1.3m2.3m

Accounts Receivable

169.6k19.7k21.3k15.7k17.4k32.6k12.0k

Prepaid Expenses

1.6k954.03.0k2.1k1.3k3.2k3.1k49.0k165.0k53.0k164.0k81.0k75.0k250.0k152.0k85.0k115.0k73.0k93.0k119.0k389.0k495.0k

Current Assets

378.5k395.3k388.7k367.0k279.2k336.8k185.0k2.0m1.5m2.1m1.6m3.0m1.9m1.5m1.8m1.5m892.0k1.9m1.3m3.8m2.1m3.3m

PP&E

15.3k13.2k16.5k14.2k15.2k10.9k8.7k

Total Assets

563.0k533.3k441.0k381.2k297.5k350.7k196.7k2.0m1.5m2.1m1.6m3.0m1.9m1.5m1.8m1.6m945.0k1.9m1.3m3.8m2.1m3.3m

Accounts Payable

14.8k14.0k12.7k12.6k3.4k10.4k1.4k638.0k808.0k797.0k1.1m1.1m643.0k874.0k1.2m936.0k1.0m905.0k289.0k261.0k271.0k493.0k

Short-term debt

6.7k6.4k7.2k6.9k7.8k250.0k250.0k250.0k250.0k296.0k298.0k50.0k300.0k300.0k259.0k232.0k103.0k

Current Liabilities

646.4k653.6k676.1k666.8k669.9k641.0k568.8k919.0k1.9m1.7m2.1m2.4m2.1m2.1m3.9m1.4m1.5m2.5m714.0k689.0k1.4m1.7m

Long-term debt

300.0k289.0k291.0k292.0k300.0k250.0k742.0k742.0k

Non-Current Liabilities

3.1m3.0m3.1m3.1m247.0k715.0k1.5m250.0k

Total Debt

6.7k6.4k7.2k6.9k7.8k300.0k3.0m3.0m3.0m296.0k298.0k300.0k2.0m25.0k300.0k259.0k974.0k742.0k103.0k

Total Liabilities

654.3k660.0k680.9k670.0k673.5k641.0k568.8k1.5m1.4m

Common Stock

86.0k86.0k86.0k86.0k86.0k86.0k86.0k30.0k30.0k32.0k32.0k36.0k37.0k4.0k4.0k5.0k5.0k5.0k6.0k7.0k7.0k7.0k

Preferred Stock

200.1k200.1k200.1k200.1k200.1k200.1k200.1k

Additional Paid-in Capital

13.4m13.4m13.5m13.5m13.5m13.5m13.5m10.9m11.0m12.8m13.1m24.7m24.9m25.1m28.7m33.5m33.6m35.8m38.5m42.2m42.7m44.7m

Retained Earnings

(13.8m)(13.9m)(14.0m)(14.0m)(14.1m)(14.1m)(14.2m)(12.9m)(14.5m)(15.5m)(16.5m)(24.4m)(25.8m)(27.0m)(30.9m)(33.4m)(34.3m)(36.6m)(38.9m)(40.3m)(43.1m)(43.5m)

Total Equity

(91.3k)(126.7k)(240.0k)(288.8k)(376.0k)(290.3k)(372.1k)(2.0m)(3.5m)(2.6m)(3.5m)338.0k(955.0k)(2.1m)(2.3m)110.0k(542.0k)(588.0k)(117.0k)2.4m724.0k1.6m

Debt to Equity Ratio

-0.1 x-0.1 x0 x0 x0 x-0.2 x-0.9 x-1.1 x-0.9 x0.9 x-0.3 x-0.1 x-0.8 x0.2 x-0.6 x-0.4 x-8.3 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0.1 x2.1 x1.4 x1.8 x0.1 x0.2 x0.2 x1.1 x0 x0.3 x0.1 x0.7 x

Financial Leverage

-6.2 x-4.2 x-1.8 x-1.3 x-0.8 x-1.2 x-0.5 x-1 x-0.4 x-0.8 x-0.5 x8.9 x-2 x-0.7 x-0.8 x14.1 x-1.7 x-3.2 x-11.4 x1.6 x3 x2.1 x

Sun BioPharma Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

247.4k(212.0k)(107.0k)(4.9m)(5.1m)(10.4m)(5.9m)(6.2m)

Depreciation and Amortization

5.6k8.8k9.6k

Accounts Receivable

32.9k(60.7k)3.3k

Accounts Payable

(10.6k)(24.1k)(3.7k)681.0k726.0k(319.0k)360.0k301.0k

Cash From Operating Activities

37.1k(35.4k)(11.5k)(3.9m)(2.4m)(3.4m)(2.4m)(2.7m)

Purchases of PP&E

(5.1k)

Cash From Investing Activities

19.1k(5.1k)124.7k500.0k

Short-term Borrowings

(25.0k)

Long-term Borrowings

(4.5k)(7.2k)(8.3k)(14.0k)(161.0k)

Cash From Financing Activities

6.9k(11.6k)(8.3k)2.7m1.9m3.1m3.6m3.8m

Net Change in Cash

63.1k(52.1k)105.0k(729.0k)(487.0k)(286.0k)1.3m1.0m

Interest Paid

1.6k1.4k1.6k145.0k57.0k11.0k67.0k14.0k

Income Taxes Paid

284.0220.0121.0

Sun BioPharma Ratios

USDFY, 2012

Debt/Equity

-0.4 x

Financial Leverage

-15 x